Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enliven Therapeutics, Inc. (Nasdaq: ELVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Enliven files a range of documents with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K describing material events.
For Enliven, Form 8-K filings are particularly relevant to investors monitoring clinical-stage and corporate milestones. Recent 8-Ks have covered topics such as quarterly financial results, leadership changes including the appointment of a new President and Chief Executive Officer, the adoption of the 2025 Inducement Equity Incentive Plan, and related compensatory arrangements. Amendments on Form 8-K/A may be used to correct or update previously furnished information, such as earnings press releases.
Periodic reports on Form 10-K and Form 10-Q (referenced in Enliven’s press releases) contain more detailed information on research and development expenses, general and administrative costs, net loss, cash, cash equivalents and marketable securities, as well as risk factors and management’s discussion and analysis. These filings help contextualize the company’s ability to fund the ENABLE Phase 1 trial of ELVN-001 and potential future studies.
On Stock Titan, users can review Enliven’s SEC filings alongside AI-powered summaries that explain key points in accessible language, highlight important sections, and help interpret complex disclosures. Real-time updates from EDGAR allow quick access to new filings, while specialized forms such as Form 4 (when available) can be used to track insider equity transactions. This page is a practical starting point for understanding Enliven’s regulatory history, financial reporting, equity plans and material corporate events related to its precision oncology programs.
Enliven Therapeutics director Jake Bauer reported a new equity award. He received a grant of stock options covering 17,126 shares at an exercise price of $0.00 per share. According to the terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director through that vesting date.
Ballal Rahul D. reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics, Inc. reported that director Rahul D. Ballal received a grant of 17,126 stock options. The transaction is coded as a grant or award and recorded with a transaction price of $0.00 per option.
According to the vesting terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as Ballal continues serving as a non-employee director through that vesting date.
Enliven Therapeutics reported new equity awards for Chief Operating Officer Anish Patel. On February 12, 2026, he received a stock option covering 120,000 shares of common stock at an exercise price of $0.00 per share, vesting 25% on February 12, 2027 and the remainder in equal monthly installments thereafter. He also acquired 20,000 restricted stock units, each representing one share of common stock, with 25% vesting on March 1, 2027 and the balance vesting in equal installments each June 1, September 1, December 1, and March 1 thereafter, while he continues as a service provider. In addition, an indirect holding of 215,011 common shares is reported as held by The Patel / Dong Family Trust, for which he serves as trustee.
Enliven Therapeutics, Inc. reported an equity compensation award to its Chief Scientific Officer, Joseph P. Lyssikatos. On February 12, 2026, he was granted a stock option for 112,500 shares of common stock at an exercise price of $0.00 per share. According to the filing, one quarter of this option vests on February 12, 2027, with the remainder vesting in equal monthly installments over the following three years, so long as he continues as a service provider.
He also received 18,750 restricted stock units (RSUs), each representing one share of common stock. One quarter of these RSUs vest on March 1, 2027, with additional portions vesting on each June 1, September 1, December 1, and March 1 thereafter, subject to continued service. The filing also notes indirect ownership of 740,188 shares of common stock held through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.
Enliven Therapeutics reported new equity awards for its Chief Financial Officer, Benjamin Hohl. He received stock options for 150,000 shares at an exercise price of $0.00 per share and 25,000 restricted stock units, each representing one share of common stock.
The option award vests over four years, with one-quarter vesting on February 12, 2027 and the remainder monthly thereafter, as long as he continues as a service provider. The RSUs vest on a similar multi-year schedule beginning March 1, 2027, with one-quarter vesting initially and the rest in equal quarterly installments.
Collins Helen Louise reported acquisition or exercise transactions in a Form 4 filing for ELVN. The filing lists transactions totaling 175,000 shares. Following the reported transactions, holdings were 150,000 shares.
An Enliven Therapeutics insider, Samuel Kintz, filed notice to sell 75,000 shares of the company’s common stock through Jefferies LLC, with an indicated aggregate market value of $2,004,000.00. The notice lists 59,000,000 common shares outstanding and targets an approximate sale date of 02/17/2026 on Nasdaq.
The 75,000 shares are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. The filing also reports recent sales over the past three months, including 43,743 shares sold on 01/09/2026 for gross proceeds of $1,089,200.70 and 20,000 shares on 01/20/2026 for $535,090.80.
Enliven Therapeutics insider Richard Heyman filed a notice of proposed sale under Rule 144 covering up to 1,230 shares of common stock. The planned sale through Jefferies LLC on the Nasdaq has an aggregate market value of $32,865.60, with 59,000,000 shares outstanding. The approximate sale date indicated is February 17, 2026. In the past three months, Heyman has sold Enliven securities in three transactions totaling 8,015 shares for $200,655.12, 4,285 shares for $107,125.60, and 1,230 shares for $32,901.55.
Enliven Therapeutics filed a notice of proposed insider sales under Rule 144. The filing covers up to 45,000 shares of common stock, with an aggregate market value of $1,202,400.00, to be sold through Jefferies LLC on or about February 17, 2026 on the NASDAQ exchange.
The 45,000 shares were acquired on August 9, 2022 via stock options from Enliven Therapeutics Inc. The filing also notes that 59,000,000 shares of common stock were outstanding. The seller represents they are not aware of undisclosed material adverse information about the company.
Vestal Point Capital has reported a significant passive ownership stake in Enliven Therapeutics, Inc. Through a fund and a managed account, Vestal Point and its CIO Ryan Wilder beneficially own 3,830,000 shares of Enliven common stock, representing 6.5% of the company’s outstanding shares.
The filing shows Vestal Point and Wilder share voting and dispositive power over these shares, while the Vestal Point fund and account are entitled to dividends and sale proceeds. The ownership percentage is based on 59,347,317 Enliven shares outstanding as of October 31, 2025. The stake is certified as being held in the ordinary course of business without the purpose of influencing control.